The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

What the results might mean for the future of other developers in the cannabinoid receptor 1 (CB1) weight-loss arena came into question after Novo Nordisk A/S unveiled phase IIa findings with ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...

Novo Nordisk braced for a congressional inquiry into the high prices of weight loss and diabetes drugs, particularly Ozempic, ...

If confirmed, he would be the first person to serve in this position which was created in 2022. Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Novo Nordisk CEO faces Senate showdown over high prices for diabetes and weight loss drugs Ozempic and Wegovy.

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company released a statement Monday highlighting the safety of its in-development obesity treatment compared with other ...

Melissa Barber, a health economist at Yale University, said during Sanders’ roundtable Tuesday that her research has shown ...